Monoclonal Antibodies (mABs)

Key Facts about Monoclonal Antibodies

Monoclonal antibodies (mAbs) are highly specific immunoglobulin molecules produced by identical immune cells derived from a single parent clone, making them a cornerstone of modern biotherapeutics in oncology, autoimmune and infectious diseases. Since the approval of the first therapeutic mAb in 1986, the field has grown into a multi-billion-USD market, with hundreds of antibody-based products approved or in clinical development worldwide.

The mAb production process is fundamentally a mammalian cell culture process. Cells used for mAb manufacturing secrete the antibody into the culture medium, where product quality is directly linked to the bioreactor environment. Critical quality attributes (CQAs) defined under cGMP guidance of the FDA and EMA — including aggregation, charge variants and glycosylation — must be tightly controlled across every stage of upstream manufacturing.

Because mAb-producing cells are shear-sensitive eukaryotic cells with complex post-translational modifications, they require gentle agitation, precise gas transfer and defined feeding strategies. This makes the choice of bioreactor system — from small-scale bioreactors for process development to single-use and stainless steel systems for commercial production — a critical driver of product titer, glycan profile and manufacturing efficiency.

Monoclonal antibody illustration – Y-shaped mAB structure for biotherapeutic bioreactor manufacturing

Typical cell types used for monoclonal antibody production

The selection of the production cell line is one of the most important steps in the monoclonal antibody manufacturing process. While several mammalian cell lines are technically suitable, the industry has strongly converged on a small number of robust, regulatory-accepted host systems for mAb production.

  • Chinese hamster ovary (CHO) cells

    (industry standard, >70% of recombinant biopharmaceuticals)

    The dominant platform for mAb production, responsible for more than 70% of all recombinant biopharmaceuticals on the market. CHO cells grow well in suspension, perform human-like post-translational modifications (especially N-glycosylation) and tolerate chemically defined, animal-component-free media — making them well suited to large-scale fed-batch and perfusion processes.

  • NS0 and Sp2/0 mouse myeloma cells

    (historical, hybridoma-based)

    Historically used for hybridoma-based mAb production. They offer good secretion capacity but are less scalable and show a different glycosylation pattern than CHO, which is why most new therapeutic antibody programs favor CHO.

  • HEK293 cells

    (human embryonic kidney)

    Mainly used for transient mAb expression during early research, candidate screening and for antibodies that require fully human glycosylation patterns. Particularly valued in Fc-engineering and biophysical characterization workflows.

  • Hybridoma cells

    (B-cell / myeloma fusion)

    The original B-cell / myeloma fusion cells used to generate monoclonal antibodies. Still highly relevant for antibody discovery and research reagents, but rarely used for large-scale therapeutic mAb manufacturing due to limited scalability compared to CHO.

Key process parameters for mAb production

Monoclonal antibody production in CHO and other mammalian cells depends on the precise control of a small number of critical process parameters. These parameters directly determine cell growth, specific productivity (qP), volumetric titer and the critical quality attributes of the mAb, especially glycan profile and aggregate level.

  • pH control

    (6.8–7.2)

    Maintained via CO₂ sparging and base addition (e.g., sodium bicarbonate). Higher pH (~7.15) tends to favor cell density, whereas a controlled pH shift to ~6.85 during the production phase can increase mAb titer and reduce byproducts such as lactate.

  • Dissolved oxygen (DO)

    (20–50%)

    Regulated by gas mixing (air/O₂) and agitation. Too low DO leads to hypoxia and drops in productivity; too high DO can cause oxidative stress and affect glycosylation.

  • Temperature and temperature shift

    (36–37 °C → 32–34 °C)

    Many industrial mAb processes use a temperature shift during the production phase to slow growth (µ) and boost specific productivity, often increasing final titer by 20–25%.

  • Dissolved CO₂

    (< 120–150 mmHg)

    Elevated dissolved CO₂ in large-scale bioreactors is inhibitory for CHO cells and can alter mAb glycosylation. It is controlled via sparger design, agitation and sparge-gas strategy.

  • Osmolality and feed strategy

    Glucose and glutamine feeds are designed to avoid lactate accumulation (typically < 30 mM) and ammonia buildup, both of which impair viability and product quality. Multi-stage feeds support intensified fed-batch titers > 10 g/L.

  • Shear and mixing

    CHO and other mammalian cells are shear-sensitive. Low impeller speeds, marine or pitched-blade impellers and controlled bubble size (micro-sparging) protect viability while ensuring sufficient kLa for oxygen transfer.

  • Viable cell density (VCD) and viability

    Key performance indicators monitored daily via off-line or at-line analytics; N-1 intensification can provide inoculum densities of 15–30 × 10⁶ cells/mL to shorten the production run by 2–3 days.

Standard process workflow for monoclonal antibody production

The standard monoclonal antibody manufacturing process follows a well-established upstream workflow that scales from early process development in small-scale bioreactors to commercial-scale mAb production. The main steps in a modern CHO-based platform are:

  1. Antigen selection and cell line development

    Identification of a disease-specific antigen, generation of a stable CHO cell line (e.g., via DHFR/MTX or GS/MSX selection) and isolation of high-producing monoclonal clones.

  2. Clone screening and scale-down characterization

    Top clones are evaluated in shake flasks and small-scale bioreactors (e.g., 250 mL – 2 L) for titer, growth, specific productivity and product quality (glycosylation, aggregation, charge variants).

  3. Seed train and N-1 intensification

    Expansion of the working cell bank through a series of cultures; N-1 perfusion can generate high-density inocula (3–5 × 10⁶ up to 30 × 10⁶ cells/mL) for high-inoculum fed-batch or perfusion processes.

  4. Inoculation of the production bioreactor

    Transfer into the production bioreactor at defined volume and density, with controlled pH, DO and temperature set points.

  5. Production phase

    Cascade control of pH, DO and temperature; bolus or continuous feeding; optional temperature shift to boost specific productivity; perfusion operation using cell retention devices such as acoustic separators (e.g., BioSep) or alternating tangential flow (ATF) for high-density processes.

  6. Process monitoring and PAT

    On-/at-line monitoring of viable cell density, titer, glucose, lactate, glutamine, ammonia and dissolved CO₂; product quality monitoring via HPLC and mass spectrometry.

  7. Harvest and clarification

    End-of-batch harvest or continuous harvest via cell retention, followed by clarification (depth filtration, centrifugation) to prepare the mAb for downstream purification (Protein A affinity, ion exchange, polishing).

Applikon bioreactor types for monoclonal antibody production

All Applikon bioreactor formats are designed as a scalable platform for monoclonal antibody production, from early process development to commercial-scale mAb manufacturing. Unified control strategies via Livit Flex and my-Control bioprocess controllers enable consistent pH, DO, temperature and feeding cascades across formats — supporting a true scale-up / scale-down approach with seamless transition from R&D to GMP.

Type Scale Key Use Cases mAb-Specific Features
Applikon MiniBio glass small-scale bioreactor 250 mL – 1000 mL mAb process development, clone screening, media and feed optimization, DoE scale-down Low media consumption, shear-optimized setup for CHO, parallel operation, perfusion-ready for high-density N-1 studies
Applikon glass autoclavable bioreactors for mAb production 2–20 L R&D and pilot-scale fed-batch and perfusion runs, scale-up/scale-down models, feed and temperature-shift studies Multi-gas sparging, multiple sensor options (pH, DO, CO₂, optical), flexible impeller configuration for shear-sensitive CHO cultures, perfusion-ready
AppliFlex ST single-use bioreactor for mAb manufacturing 0.5–15 L Flexible mAb clinical and small-scale GMP production, rapid campaign changeover, process optimization, scale-up/scale-down 3D-printed customizable single-use vessels, pre-sterilized, reduced cross-contamination risk, fast setup for high-throughput mAb production, perfusion-ready
Stainless-steel bioreactors for large-scale mAb production and continuous perfusion from 20 L to 5,000 L Commercial-scale mAb manufacturing, repeated fed-batch and perfusion campaigns, platform biopharmaceutical production CIP/SIP capability, robust shear control at large scale, scalable agitation and sparger design, perfusion-ready for intensified bioprocessing
Capabilities

Why Choose the Applikon AppliFlex ST for mAB Manufacturing?

The Applikon AppliFlex ST single-use bioreactor stands out in the monoclonal antibody manufacturing landscape for its unique combination of precision, scalability, efficiency, and versatility. It plays a critical role in enabling the efficient and scalable production and development of these vital therapeutic agents.

As a leading tool for mAB production, the AppliFlex ST allows you to dive straight into your bioprocess with quick setup and easy operation — reducing production times and costs while enhancing the overall efficiency of the mAB manufacturing process.
Step-by-Step

Detailed Process Guide for mAB Production

Optimizing monoclonal antibody production with Applikon bioreactors involves a series of carefully coordinated steps — from bioreactor and antigen selection through to cell expansion and cultivation under ideal conditions

Advantages of the AppliFlex ST for mAB Manufacturing

  • Precision and Control

    Precision and Control

    The AppliFlex ST offers unique control over environmental conditions — ensuring optimal cell growth and productivity throughout the mAB manufacturing process.

  • Scalability

    Scalability

    Available in different volumes, the AppliFlex ST offers scientists the opportunity to develop a process and subsequently scale it up to commercial-scale mAB production.

  • Efficiency

    Efficiency

    Quick setup and easy operation allows you to dive straight into your bioprocess — reducing production times and costs and enhancing the overall efficiency of mAB manufacturing.

  • Versatility

    Versatility

    Customization options make the AppliFlex ST a versatile tool for different mAB production processes — supporting a wide range of cell types and cultivation strategies.

End Products

Vaccines

Vaccines
Learn more

Viral Vectors

Viral Vectors
Learn more
CTA Background

Looking for the Right Bioprocess Solution?

Our specialists support you throughout the entire bioprocess lifecycle — from system selection and application design to implementation, optimization, and long-term operation. We work closely with you to ensure reliable, compliant, and scalable solutions tailored to your requirements.

Talk to Our Experts

Scientific Solutions Start Here

Reach out to discuss innovative approaches for your project.

Steinacker 15, CH-4565 Recherswil
+41 34 531 08 20
[email protected]
CHE-166.210.273
Contact Form EN

FAQ - Monoclonal Antibodies (mABs)

The production of monoclonal antibodies primarily uses Chinese hamster ovary (CHO) cells as the production organism. CHO cells are extensively used in the biopharmaceutical industry due to their exceptional ability to perform complex post-translational modifications — crucial for the functional efficacy of therapeutic proteins. Advanced techniques including transcriptomics, proteomics, and methotrexate-based amplification are used to enhance genetic expression and significantly increase mAB productivity. While hybridoma technology — fusing B-cells with myeloma cells — is foundational, CHO cells are preferred for their superior scalability and adaptability in large-scale manufacturing.

Monoclonal antibody production can be carried out using batch, fed-batch, perfusion, or chemostat processes — each offering different advantages in terms of productivity, flexibility, and resource usage. Applikon bioreactors support all these process forms, ensuring maximum productivity and flexibility to meet various production needs. The choice of process type is typically based on the product requirements and the overall goals of the bioprocess.

The Applikon AppliFlex ST stands out for its precision and control over environmental conditions, scalability across different production volumes, efficiency through quick setup and easy operation — reducing production times and costs — and versatility through customization options that support a wide range of cell types and cultivation strategies. It allows manufacturers to dive straight into their bioprocess and scale it up to commercial-scale mAB production, making it a critical asset in biopharmaceutical development.

Monoclonal antibodies offer unparalleled specificity in targeting diseases — they are particularly used in oncology (cancer treatment), autoimmune diseases, and infectious diseases. Their groundbreaking mechanism allows them to target specific disease markers with high precision, making them one of the most important classes of therapeutic agents in modern medicine.

Applikon bioreactors provide precise control over temperature, pH, and dissolved oxygen levels — the three parameters essential for maximizing cell growth and antibody yield during mAB production. This optimized environment supports robust CHO cell expansion and efficient antibody production, ensuring a consistent and reliable supply of high-quality monoclonal antibodies throughout the manufacturing process.